Schering building diabetes presence de Novo: Prandin and insulin co-promotions with Novo Nordisk.
SCHERING ENTERING DIABETES MARKET VIA NOVO PRANDIN, INSULIN LINE copromotion agreement announced by the two firms Jan. 28. The two companies signed a multi-year agreement to copromote Novo Nordisk's recently approved type 2 diabetes agent Prandin (repaglinide), along with Novo's full range of insulin products and devices. Prandin was approved Dec. 22 for oral treatment of type 2 diabetes as monotherapy or in combination with Bristol-Myers Squibb's Glucophage (metformin). At that time, Novo said that it would launch the product in the spring after finding a marketing partner ("The Pink Sheet" Jan. 5, p. 15).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth